Telemedicine strategy of the European Reference Network ITHACA for the diagnosis and management of patients with rare developmental disorders.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
25 04 2020
Historique:
received: 11 11 2019
accepted: 03 03 2020
entrez: 27 4 2020
pubmed: 27 4 2020
medline: 22 6 2021
Statut: epublish

Résumé

The European Reference Networks, ERNs, are virtual networks for healthcare providers across Europe to collaborate and share expertise on complex or rare diseases and conditions. As part of the ERNs, the Clinical Patient Management System, CPMS, a secure digital platform, was developed to allow and facilitate web-based, clinical consultations between submitting clinicians and relevant international experts. The European Reference Network on Intellectual Disability, TeleHealth and Congenital Anomalies, ERN ITHACA, was formed to harness the clinical and diagnostic expertise in the sector of rare, multiple anomaly and/or intellectual disability syndromes, chromosome disorders and undiagnosed syndromic disorders. We present the first year results of CPMS use by ERN ITHACA as an example of a telemedicine strategy for the diagnosis and management of patients with rare developmental disorders. ERN ITHACA ranked third in telemedicine activity amongst 24 European networks after 12 months of using the CPMS. Information about 28 very rare cases from 13 different centres across 7 countries was shared on the platform, with diagnostic or other management queries. Early interaction with patient support groups identified data protection as of primary importance in adopting digital platforms for patient diagnosis and care. The first launch of the CPMS was built to accommodate the needs of all ERNs. The ERN ITHACA telemedicine process highlighted a need to customise the CPMS with network-specific requirements. The results of this effort should enhance the CPMS utility for telemedicine services and ERN-specific care outcomes. We present the results of a long and fruitful process of interaction between the ERN ITHACA network lead team and EU officials, software developers and members of 38 EU clinical genetics centres to organise and coordinate direct e-healthcare through a secure, digital platform. The variability of the queries in just the first 28 cases submitted to the ERN ITHACA CPMS is a fair representation of the complexity and rarity of the patients referred, but also proof of the sophisticated and variable service that could be provided through a structured telemedicine approach for patients and families with rare developmental disorders. Web-based approaches are likely to result in increased accessibility to clinical genomic services.

Sections du résumé

BACKGROUND
The European Reference Networks, ERNs, are virtual networks for healthcare providers across Europe to collaborate and share expertise on complex or rare diseases and conditions. As part of the ERNs, the Clinical Patient Management System, CPMS, a secure digital platform, was developed to allow and facilitate web-based, clinical consultations between submitting clinicians and relevant international experts. The European Reference Network on Intellectual Disability, TeleHealth and Congenital Anomalies, ERN ITHACA, was formed to harness the clinical and diagnostic expertise in the sector of rare, multiple anomaly and/or intellectual disability syndromes, chromosome disorders and undiagnosed syndromic disorders. We present the first year results of CPMS use by ERN ITHACA as an example of a telemedicine strategy for the diagnosis and management of patients with rare developmental disorders.
RESULTS
ERN ITHACA ranked third in telemedicine activity amongst 24 European networks after 12 months of using the CPMS. Information about 28 very rare cases from 13 different centres across 7 countries was shared on the platform, with diagnostic or other management queries. Early interaction with patient support groups identified data protection as of primary importance in adopting digital platforms for patient diagnosis and care. The first launch of the CPMS was built to accommodate the needs of all ERNs. The ERN ITHACA telemedicine process highlighted a need to customise the CPMS with network-specific requirements. The results of this effort should enhance the CPMS utility for telemedicine services and ERN-specific care outcomes.
CONCLUSIONS
We present the results of a long and fruitful process of interaction between the ERN ITHACA network lead team and EU officials, software developers and members of 38 EU clinical genetics centres to organise and coordinate direct e-healthcare through a secure, digital platform. The variability of the queries in just the first 28 cases submitted to the ERN ITHACA CPMS is a fair representation of the complexity and rarity of the patients referred, but also proof of the sophisticated and variable service that could be provided through a structured telemedicine approach for patients and families with rare developmental disorders. Web-based approaches are likely to result in increased accessibility to clinical genomic services.

Identifiants

pubmed: 32334637
doi: 10.1186/s13023-020-1349-1
pii: 10.1186/s13023-020-1349-1
pmc: PMC7183125
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103

Références

Clin Genet. 2016 Jan;89(1):27-33
pubmed: 25683496
J Telemed Telecare. 2006;12(4):182-5
pubmed: 16774698
Public Health Genomics. 2016;19(1):19-24
pubmed: 26447648
Twin Res Hum Genet. 2011 Aug;14(4):343-6
pubmed: 21787118
BMJ. 1990 Jul 14;301(6743):98-102
pubmed: 2390594
Orphanet J Rare Dis. 2017 Aug 7;12(1):137
pubmed: 28784158
Rural Remote Health. 2017 Apr-Jun;17(2):3965
pubmed: 28564548
Eur J Hum Genet. 2014 Mar;22(3):327-32
pubmed: 23838594
Paediatr Int Child Health. 2017 Aug;37(3):155-157
pubmed: 28498062
J Glob Health. 2018 Dec;8(2):020414
pubmed: 30574293
N Engl J Med. 2014 Jun 19;370(25):2418-25
pubmed: 24941179
Genet Med. 2017 Nov;19(11):1260-1267
pubmed: 28471436
Genet Med. 2012 Sep;14(9):765-76
pubmed: 22498847

Auteurs

Michael Smith (M)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.

Elizabeth Alexander (E)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.

Ruta Marcinkute (R)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.
Department of Human and Medical Genetics, Institute of Biomedical Sciences of the Faculty of Medicine of Vilnius University, M. K. Čiurlionio g. 21/27, LT-03101, Vilnius, Lithuania.

Dorica Dan (D)

Romanian National Alliance for Rare Diseases RONARD, 29 Avram Iancu, etaj III, 450143, Zalau, Romania.

Myfanwy Rawson (M)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.

Siddharth Banka (S)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.
Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.

Jason Gavin (J)

European Commission, DG Health and Food Safety, Information Systems, Rue Breydel 4 / Breydelstraat 4, Building B232 - 1049, Brussels, Belgium.

Hany Mina (H)

Open Applications Consulting Ltd., Avoca House, 191 Parnell St, Rotunda, Dublin 1, Ireland.

Con Hennessy (C)

Open Applications Consulting Ltd., Avoca House, 191 Parnell St, Rotunda, Dublin 1, Ireland.

Florence Riccardi (F)

Medical Genetics Department, La Timone Hospital, Marseilles Public University Hospital, 278 Rue Saint-Pierre, 13005, Marseille, France.

Francesca Clementina Radio (FC)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146, Rome, Italy.

Marketa Havlovicova (M)

Department of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and University Hospital Motol, V Úvalu 84, 150 06, Prague 5, Czech Republic.

Matteo Cassina (M)

Clinical Genetics Unit, Department of Women's and Children's Health, University of Padova, Via Giustiniani, 3 - 35128, Padova, Italy.

Adela Chirita Emandi (AC)

Discipline of Genetics, Victor Babeș University of Medicine and Pharmacy, Piața Eftimie Murgu 2, 300041, Timișoara, Romania.
"Louis Turcanu" Clinical Emergency Hospital for Children, Strada Doctor Iosif Nemoianu 2, 300011, Timișoara, Romania.

Melanie Fradin (M)

Department of Medical Genetics, CHU de Rennes, 2 rue Henri Le Guilloux, 35033, Rennes cedex 9, France.

Lianne Gompertz (L)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.

Ann Nordgren (A)

Department of Molecular Medicine and Surgery, Center for Molecular Medicine and Department of Clinical Genetics, Karolinska University Hospital, 171 77, Stockholm, Sweden.

Rasa Traberg (R)

Department of Genetics and Molecular Medicine, Hospital of Lithuanian University of Health Sciences Kauno klinikos, Eivenių Str. 2, LT-50161, Kaunas, Lithuania.

Massimiliano Rossi (M)

Department of Medical Genetics, CHU de Lyon, 162 Avenue Lacassagne, 69003, Lyon, France.

Aurelién Trimouille (A)

Genetic Department, Hospices Civils de Lyon and CRNL, GENDEV Team, INSERM U1028, U1028 / UMR 5292, Bd Pinel - 69677, Bron Cedex, France.

Rasika Sowmyalakshmi (R)

Department of Genetics, AP-HP Robert-Debré University Hospital, Bd Sérurier, 75019, Paris, France.

Bruno Dallapiccola (B)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146, Rome, Italy.

Alessandra Renieri (A)

Medical Genetics, Department of Medical Biotechnologies, University of Siena, Policlinico Santa Maria alle Scotte, Viale Mario Bracci, 16, 53100, Siena, Italy.

Laurence Faivre (L)

Department of Medical Genetics and Centre of Reference for Developmental Anomalies and Malformative syndromes, CHU de Dijon, 14 Rue Paul Gaffarel, 21000, Dijon, France.

Bronwyn Kerr (B)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.
Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.

Alain Verloes (A)

Department of Genetics, AP-HP Robert-Debré University Hospital, Bd Sérurier, 75019, Paris, France.
Université Paris Diderot, 5 Rue Thomas Mann, 75013, Paris, France.

Jill Clayton-Smith (J)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.
Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.

Sofia Douzgou (S)

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK. sofia.douzgou@mft.nhs.uk.
Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK. sofia.douzgou@mft.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH